Login to Your Account

San Antonio Breast Cancer Symposium 2017

SABCS at 40: Though nobody's perfect, no midlife crisis

By Anette Breindl
Senior Science Editor

Thursday, December 7, 2017

SAN ANTONIO – One of the most anticipated presentations on the first day of the 2017 San Antonio Breast Cancer Symposium (SABCS) was the B-47 study, which investigated the use of adjuvant Herceptin (trastuzumab, Roche Holding AG) in patients with low HER2 expression.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription